STAT+: Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.

ChemoCentryx is being purchased for $52 per share, or a 116% premium to its Wednesday closing price.

Continue to STAT+ to read the full story…